ARENDT TOOK THE LEAD IN PREPARING AND PASSPORTING FOR THE ADMISSION TO TRADING OF ALVOTECH'S SHARES ON NASDAQ ICELAND MAIN MARKET
DEAL - STOCK EXCHANGE - UPLISTING
Luxembourg, December 2022 – Arendt & Medernach advised Alvotech, a fully integrated specialty biopharmaceutical group focused on the development and manufacturing of high-quality biosimilar medicines, with the uplisting of its shares from Nasdaq Iceland First North Growth Market to the Nasdaq Iceland Main Market, the regulated market operated by Nasdaq Iceland.
Arendt took the lead in preparing and passporting the prospectus under the EU Prospectus Regulation for the admission to trading of Alvotech's shares on Nasdaq Iceland Main Market.
Arendt team involved:
- Corporate Law, Mergers & Acquisitions: Fouzia Benyahia, Counsel, Pierre Maucet, Senior Associate, Alexander Olliges, Partner and Alexandre Tangton, Senior Associate
- Finance & Capital Markets: Burak Aytaç and Sean Micaleff-Trigona, Associates, Milos Vulevic, Senior Associate, François Warken, Partner and Serge Zeien, Counsel
- Tax Law: Vilho Lammi, Senior Associate, and Jan Neugebauer, Partner